---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066930"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:42:39.085950+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q1 revenue down 21% to $86.7M; net loss widens to $18.8M; FY guidance reaffirmed

## Summary
- Net revenue $86.7M, down 21% YoY; Advanced Wound Care fell 23% to $79.9M; Surgical & Sports Medicine up 11% to $6.8M.
- Net loss $18.8M ($0.17 loss per share) vs $2.1M loss in Q1 2024; adjusted EBITDA loss $12.5M vs income $2.6M.
- Cash $110.5M, no debt; cash used in operations $19.9M vs $10.2M in prior year.
- FY2025 revenue guidance reaffirmed at $480M-$535M; updated net income guidance $4.7M-$34.0M (from prior range).
- ReNu BLA submission on track for end of 2025; second phase 3 study patient enrollment expected by end of Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-066930
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017025066930/0000950170-25-066930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017025066930/orgo-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066930
- JSON: https://secwatch.observer/filing/0000950170-25-066930.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066930.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.